Abstract
Over three decades, cruzain, the principal cysteine protease of Trypanosoma cruzi and a validated drug target for Chagas disease, has accumulated 215 inhibitors with IC 50 ≤ 1 μM, more than 30 crystal structures, and no clinical candidates. This review argues that the resulting translational paradox reflects not target invalidity, but a persistent strategic mismatch between how cruzain inhibitors have been optimised and what intracellular efficacy requires. Across peptidyl vinyl sulfones, non‐peptidic scaffolds, and thiosemicarbazones, enzymatic potency has been systematically prioritised over the coupled determinants of intracellular exposure: permeability, metabolic stability, and cathepsin selectivity. Each inhibitor class fails for a distinct proximal reason, and these failures converge on the same optimisation bias. Computational approaches (docking, molecular dynamics, free‐energy perturbation and machine‐learning QSAR) have been applied with increasing sophistication, but against affinity‐centred objectives that underrepresent exposure constraints. As its principal contribution, this work proposes a multiparametric optimisation framework, provisional viability benchmarks, and a feasibility‐envelope concept that reframes cruzain inhibitor discovery as a constraint‐satisfaction rather than a potency‐maximisation problem. The framework outlines provisional quantitative criteria that a next‐generation cruzain lead would likely need to satisfy and explains why structurally tractable intracellular cysteine protease targets can remain clinically unrealised.
Funding Information
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (447623/2024‐9)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (440006/2022‐8)
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ‐JCNE E‐26/201.268/2021)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Finance Code 001)

This publication has 63 references indexed in Scilit: